DYAX 13.15 Dyax Corp $DYAX Hit a 52 week high of 13.24

New Post Public Reply Private Reply Replies (0) Message Board

Nov 12, 2014 at 11:40 AM

DYAX 13.15 Dyax Corp $DYAX Hit a 52 week high of 13.24 Closing the day 09:45 at 13.15 -0.08 -0.60% With a day low of 13.03 and a total volume of 33,290.

DYAX Recent Posts: http://investorshangout.com/Dyax-Corp-DYAX-53955/

DYAX Dyax Corp Recent Headline News

Dyax Up 73.8% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Mon Nov 10, 4:46PM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 6 months, Dyax has returned 73.76% as of today's recent price of $13.18.
DYAX: 13.25 (+0.02)

Why Dyax (DYAX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:42AM CST
Dyax's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
DYAX: 13.25 (+0.02)

Can Dyax (DYAX) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:49AM CST
Dyax possess a positive long term growth rate and favorable Zacks Rank
DYAX: 13.25 (+0.02)

Dyax Shares Up 62.1% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 62.07% as of today's recent price of $12.29.
DYAX: 13.25 (+0.02)

Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930
Business Wire - Mon Nov 03, 6:30AM CST
Dyax Corp. (NASDAQ: DYAX) today announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema (HAE) attacks.
DYAX: 13.25 (+0.02)

BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 319.94 (-4.65), AMAG: 34.71 (-0.17), BIND: 9.81 (unch), DYAX: 13.25 (+0.02)

Update: Biotech Dyax Exceeds Q3 Estimates With The Future Looking Bright
David Zanoni - at Seeking Alpha - Thu Oct 30, 11:15AM CDT

DYAX: 13.25 (+0.02)

Will Dyax (DYAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:04AM CDT
Will Dyax (DYAX) Continue to Surge Higher?
DYAX: 13.25 (+0.02)

Dyax ups earnings 87% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:53AM CDT

DYAX: 13.25 (+0.02)

Dyax's (DYAX) CEO Gustav Christiansen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 7:54PM CDT

DYAX: 13.25 (+0.02)

Dyax beats Street 3Q forecasts
Automated Insights - Tue Oct 28, 4:48PM CDT
BURLINGTON, Mass. (AP) _ Dyax Corp. (DYAX) on Tuesday reported a loss of $816,000 in its third quarter.
DYAX: 13.25 (+0.02)

Dyax (DYAX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:55PM CDT

DYAX: 13.25 (+0.02)

Dyax beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:16PM CDT

DYAX: 13.25 (+0.02)

Dyax Corp. Announces Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:01PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers -including the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.25 (+0.02)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 4:35PM CDT

EA: 40.95 (-0.19), BXP: 127.15 (-0.49), AMP: 129.76 (-0.60), MRCY: 13.43 (+0.01), BLDP: 2.65 (-0.14), ESRX: 77.43 (-0.31), AJG: 47.95 (-0.23), NANO: 14.27 (-0.11), CAP: 22.60 (-0.04), EXTR: 3.74 (-0.03), HTA: 12.38 (-0.03), AEC: 19.44 (-0.08), MCK: 202.31 (-0.81), BGFV: 13.07 (+0.08), FB: 73.84 (-0.77), ARI: 16.52 (+0.01), EXP: 88.25 (-0.06), MWA: 9.91 (unch), DYAX: 13.25 (+0.02), FARO: 55.24 (-0.14), NFX: 33.61 (-0.01), KONA: 22.27 (-0.90), AZPN: 38.00 (+0.07), GILD: 107.07 (-0.94), HIW: 42.44 (-0.24), PEI: 21.64 (+0.04), GFIG: 4.81 (-0.06), CHRW: 72.11 (+0.36), HURN: 69.13 (-0.58), DLR: 68.51 (+0.06), HLIT: 6.86 (+0.05), AMCC: 6.32 (-0.03), INVN: 14.59 (+0.06), BOOM: 17.12 (-0.10), CINF: 51.18 (unch), KIM: 24.65 (-0.13), OI: 25.71 (-0.08), GPRE: 34.16 (-0.11), EPR: 56.87 (-0.64), APC: 93.05 (+0.04), IPHI: 14.48 (-0.18), HTS: 19.03 (+0.05), MAR: 76.94 (-0.20), INAP: 8.06 (unch), CRAY: 33.97 (-0.50), FEIC: 82.98 (-0.81), FISV: 69.84 (unch), DNB: 124.03 (+0.46), AFG: 60.54 (-0.08), CEB: 74.81 (+0.11), KEYW: 10.94 (-0.06), PLT: 52.32 (-0.01), MAC: 68.67 (-0.70), CHMT: 23.51 (+0.03), AFL: 59.10 (+0.06), CBT: 47.14 (+0.09), EIX: 62.25 (-0.96), EQR: 69.51 (-0.45)

Shares of DYAX Up 41.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 27, 9:38AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 41.60% as of today's recent price of $10.74.
DYAX: 13.25 (+0.02)

Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 13.78 (-0.35), BCRX: 10.69 (-0.13), NBIX: 19.05 (-0.15), ONTY: 1.66 (-0.01), DYAX: 13.25 (+0.02)

Dyax Has Returned 31.6% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Oct 20, 9:12AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 31.58% as of today's recent price of $9.98.
DYAX: 13.25 (+0.02)

Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast
Business Wire - Tue Oct 14, 7:00AM CDT
Dyax Corp. (NASDAQ

YAX) will host a webcast and conference call, including an open question and answer session, Tuesday, October 28, 2014. During the call, management will discuss the Company's financial results for the third quarter 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.25 (+0.02)

Dyax Up 25.6% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Fri Oct 10, 5:12PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 25.64% as of today's recent price of $9.53.
DYAX: 13.25 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BrightPlan's AI-Powered Growth: Series C Fuel

Series C Funding Ignites BrightPlan's Ambitions Ever seen a company that's ready to roll with the punches and come out stronger? That's BrightPlan for you. They're pushing the boundaries again, bagging new capital in this Series C round, steered by the seasoned folks over at ABS Capital Partners. Now, here's the thing: We're talking about a 230% revenue surge over just...

IDX Expands, Enhances Team Amid 56% H1 Growth

IDX's Aggressive Global Expansion Here's a tip from a trader who’s seen cycles rise and fall: watch the movers who're playing the long game, putting down roots worldwide while making headway in the data game. IDX has clearly mapped out this trajectory as evidenced by its recent grab in the global strategic communications ring. IDX's bustling around like a squirrel...

Mandeville Pests: Health Dangers Lurking at Home

Pest Trouble Brewing in Mandeville: A Health Alert There’s a storm brewing in Mandeville, Louisiana, and it's not the kind you can see rolling in on the horizon. We're talking about those sneaky pests going unnoticed in our homes. Folks, these pests aren't just a nuisance; they're ticking time bombs for public health. Take it from J&J Exterminating, who know a thing or...

Tiger Group to Auction Huge Window Manufacturing Plant

Glass & Vinyl Ambitions: A New Chapter Who would have guessed? The seasoned window maker Showcase Window and Door Company is putting its prime manufacturing facility up for grabs. The online auction, orchestrated by Tiger Group, kicks off September 10, and it's sure to stir up some excitement in the industry. With picking up operations now within reach, it feels like...

ASCEND® Cladding Unveils New Profiles & Texture Variety

New Options for Creative Home Exteriors Amid today's housing market rollercoaster, a sprinkle of bold innovation in building materials can make a statement—and that's precisely what Associated Materials Innovations (AMI) is banking on with their latest beef-up in the ASCEND® Composite Cladding lineup. Introduced out of Cuyahoga Falls on Sept. 8, 2026, this expansion...

Innventure Faces Major Lawsuit Amidst Market Turmoil

The Plot Thickens with Innventure's DarkNX Project Buckle up, fellow market sling-riders; the Innventure tale is a rocky one for the books. Imagine this: You’ve plunked down your hard-earned cash on Innventure Inc. (NASDAQ: INV), lured by their glowing pronouncements about a supposed golden egg project, the Accelsius DarkNX data-center deal. A big talk about...

Celebree Elevates Early Ed with New Certification Push

A New Standard in Early Childhood Education In the cutthroat world of childcare and early education, just meeting the state standards ain't cutting it anymore. Celebree School, known for its infant, toddler, and preschool programs, is shaking things up with its 'Celebree Certified' initiative, setting a brand-new benchmark for teacher readiness that's far beyond the usual...

AllyGPO Shines as Top Innovator in Health Tech

Innovative Excellence in Healthcare Tech It's not every day you see a specialty group purchasing organization like AllyGPO snagging a spot on Fast Company's esteemed list of Best Workplaces for Innovators. Making it into the top half at number 40 in 2026, it’s a testament to a company really leaning into employee-driven innovation. And, buddy, this ain't just corporate...

Spot the Signs: Early Gum Disease Insights from Experts

Why Early Detection of Gum Disease Matters Let's dive right into the crux of things. Gum disease, that sneaky antagonist of oral health, starts unassumingly. You brush, you floss, but those gums might still bleed—ever noticed? Dr. Marian Burgard of Fairport Family Dental has a thing or two to say about this, enlightening us through an insightful piece by HelloNation....

Alif Semiconductor Unveils StartKit for Edge AI MCU Fam

Here's some clarity amidst the storm of buzzwords: Alif Semiconductor has rolled out something the market's been howling for—Edge AI that doesn't break the bank. It's less about slick press releases and more about real-world implications. We're talking accessibility with their dirt-cheap, small-form-factor StartKit platform for Ensemble and Balletto microcontrollers....